Gastric & Breast Cancer e-journal
DOI: 10.2122/gbc.2011.0150
OPINION
|
Challenges in reaching true robust novel breast cancer markers
|
|
Affiliation: Professor Franco Roviello, Via A. De Gasperi, 5-53100 Siena, Italy
E-mail : roviello@unisi.it
|
ABSTRACT
Unlike other common solid tumors, rapid advances and successful translation of basic science discoveries in the risk-based personalized prevention ( BRCA1/2) and tailored trastuzumab treatment (HER2 - positive disease) has been made for breast cancer. Despite this progress, for the vast majority of women who will develop breast no predictive marker has been identified to predict their individual's risk. In the treatment setting, micrometastases or gene-expression signatures have not met the expectations for personalized prediction of response to specific therapies. Here, I discuss the exciting perspectives of modern translational research including breast cancer genome sequencing and functional regulatory networks to discover novel robust biomarkers to change prevention and treatment strategies.
(Citation: Gastric & Breast Cancer 2011; 10(1): 36-42)
|
|
| You can have an online full-text access and a PDF of this article: |
- Either purchase this paper for €33 EUR. Please, click here
|
|
- Or through one year subscription PayPal
|
|
